The study was designed to assess the steady-state pharmacokinetic profile of paroxetine after 14 day repeated daily dosing of the controlled release tablet formulation (25 mg) in healthy Chinese subjects.

Inclusion criteria:

• 19-45 years healthy Chinese subjects
• Body weight > 50 kg
• BMI between 19-25
• serological negative for HIV, syphilis and hepatitis B and C
• no abnormalities in ECG
• Female with negative pregnancy and male has no plan to have a child during and 3 months after the study.

Exclusion criteria:

• History of chronic physical/mental disease, current disease and concomitant medication